SCHEMBL12409291

SCHEMBL12409291

CN1CCN(c2ccc(-c3cnc4c(Nc5cccc(OC(F)(F)C(F)F)c5)nccn34)cn2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 3/20 0.46
MAPKAPK5 Q8IW41 1/20 0.42
CTSC P53634 1/20 0.42
FYN P06241 6/20 0.41
ABL1 P00519 2/20 0.41
BCR P11274 2/20 0.41
PRKCA P17252 2/20 0.39
TTK P33981 1/20 0.38
CCNB2 O95067 1/20 0.38
CCNE2 O96020 1/20 0.38
CDK1 P06493 1/20 0.38
FGFR1 P11362 1/20 0.38
CDK4 P11802 1/20 0.38
CCNB1 P14635 1/20 0.38
CCNA2 P20248 1/20 0.38
FGFR2 P21802 1/20 0.38
FGFR4 P22455 1/20 0.38
FGFR3 P22607 1/20 0.38
CCND1 P24385 1/20 0.38
CCNE1 P24864 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14767492 0.95 PIM1 (0.45) PIM1MAPKAPK5CTSCFYNABL1
SCHEMBL3466285 0.85 CTSC (0.55) MAPKAPK5CTSCFYNTTKBRAF
SCHEMBL8246219 0.81 FYN (0.53) MAPKAPK5CTSCFYNTTKEGFR
SCHEMBL3469478 0.81 ABL1 (0.44) PIM1CTSCFYNABL1BCR
SCHEMBL3469414 0.79 ABL1 (0.43) CTSCFYNABL1BCRPRKCA
SCHEMBL13937668 0.78 PIM1 (0.36) PIM1MAPKAPK5FYNABL1BCR
SCHEMBL8246793 0.73 AURKA (0.59) MAPKAPK5FYNTTKMAP4K4
SCHEMBL13344064 0.71 CCNB2 (0.43) PIM1CTSCABL1BCRPRKCA
SCHEMBL10169171 0.70 MAPKAPK5 (0.64) MAPKAPK5FYN
SCHEMBL3467848 0.70 TTK (0.56) MAPKAPK5FYNTTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS CYP3A5, HAVCR2, CYP3A43 PIM1 429/4885MAPKAPK5 833/4885CTSC 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.